A Case of a Patient with Atezolizumab-induced Encephalitis and Hepatocellular Carcinoma.
作者信息
Otomo Kakeru, Fujita Masashi
机构信息
Department of Gastroenterology, Fukushima Medical University School of Medicine, Japan.
出版信息
Intern Med. 2025 Jul 1;64(13):2089. doi: 10.2169/internalmedicine.4865-24. Epub 2024 Dec 5.
Abstract
摘要
相似文献
1
A Case of a Patient with Atezolizumab-induced Encephalitis and Hepatocellular Carcinoma.一例阿替利珠单抗诱发脑炎合并肝细胞癌患者的病例
Intern Med. 2025 Jul 1;64(13):2089. doi: 10.2169/internalmedicine.4865-24. Epub 2024 Dec 5.
2
Patient with Atezolizumab-induced Encephalitis in Hepatocellular Carcinoma.肝细胞癌患者发生阿替利珠单抗诱导的脑炎。
Intern Med. 2025 Apr 15;64(8):1181-1187. doi: 10.2169/internalmedicine.4321-24. Epub 2024 Sep 11.
3
Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma-a multicentric study.阿替利珠单抗/贝伐珠单抗治疗不可切除肝细胞癌的安全性和有效性——一项多中心研究
BMC Cancer. 2025 Jul 1;25(1):1026. doi: 10.1186/s12885-025-14400-9.
4
Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma.单细胞RNA测序衍生的特征定义了晚期肝细胞癌对阿替利珠单抗+贝伐单抗的反应模式。
J Hepatol. 2025 Jun;82(6):1036-1049. doi: 10.1016/j.jhep.2024.12.016. Epub 2024 Dec 19.
5
The use of durvalumab and tremelimumab after atezolizumab and bevacizumab in patients with hepatocellular carcinoma: case report and literature review.阿替利珠单抗和贝伐单抗治疗后使用度伐鲁单抗和曲美木单抗治疗肝细胞癌患者：病例报告及文献综述
Immunotherapy. 2025 Jul 28:1-8. doi: 10.1080/1750743X.2025.2539064.
6
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients.阿替利珠单抗联合贝伐珠单抗对比乐伐替尼用于 Child Pugh B 不可切除肝细胞癌患者的生存结局。
J Cancer Res Clin Oncol. 2023 Aug;149(10):7565-7577. doi: 10.1007/s00432-023-04678-2. Epub 2023 Mar 28.
7
Evaluating the cost-effectiveness of atezolizumab-bevacizumab in advanced hepatocellular carcinoma: Insights from Taiwan.评估阿替利珠单抗联合贝伐珠单抗治疗晚期肝细胞癌的成本效益：来自台湾的见解。
J Food Drug Anal. 2025 Jun 13;33(2):163-171. doi: 10.38212/2224-6614.3542.
8
Tumor-suppressing multi-enterobacteria and PD-1/PD-L1 immune checkpoint inhibitor combination improves the outcome of hepatocellular carcinoma therapy.抑癌多肠道细菌与PD-1/PD-L1免疫检查点抑制剂联合应用可改善肝细胞癌治疗效果。
Front Immunol. 2025 Jun 20;16:1598436. doi: 10.3389/fimmu.2025.1598436. eCollection 2025.
9
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study.阿替利珠单抗联合贝伐珠单抗或仑伐替尼治疗肝细胞癌患者的临床结局：一项多中心真实世界研究。
J Cancer Res Clin Oncol. 2023 Aug;149(9):5591-5602. doi: 10.1007/s00432-022-04512-1. Epub 2022 Dec 13.
10
Retrospective Multicentre Real-Life Study Evaluating the Efficacy of Atezolizumab Combined with Bevacizumab for the Treatment of Metastatic Hepatocellular Carcinoma: HIREAL Study.评估阿替利珠单抗联合贝伐单抗治疗转移性肝细胞癌疗效的回顾性多中心真实世界研究：HIREAL研究
J Hepatocell Carcinoma. 2025 Jul 1;12:1279-1286. doi: 10.2147/JHC.S521130. eCollection 2025.
本文引用的文献
1
Before a Diagnosis of Atezolizumab and Bevacizumab-associated Encephalitis Is Made, all other Possible Causes Should be Ruled Out.在做出阿替利珠单抗和贝伐单抗相关脑炎的诊断之前，应排除所有其他可能的病因。
Intern Med. 2025 Jul 1;64(13):2088. doi: 10.2169/internalmedicine.4744-24. Epub 2024 Dec 5.
2
Patient with Atezolizumab-induced Encephalitis in Hepatocellular Carcinoma.肝细胞癌患者发生阿替利珠单抗诱导的脑炎。
Intern Med. 2025 Apr 15;64(8):1181-1187. doi: 10.2169/internalmedicine.4321-24. Epub 2024 Sep 11.
3
A clinical approach to diagnosis of autoimmune encephalitis.自身免疫性脑炎的临床诊断方法
Lancet Neurol. 2016 Apr;15(4):391-404. doi: 10.1016/S1474-4422(15)00401-9. Epub 2016 Feb 20.
4
Non-convulsive status epilepticus and non-convulsive seizures in neurological ICU patients.神经重症监护病房患者的非惊厥性癫痫持续状态和非惊厥性癫痫发作
Neurocrit Care. 2015 Apr;22(2):202-11. doi: 10.1007/s12028-014-0070-0.
5
The epidemiology of convulsive and nonconvulsive status epilepticus.惊厥性和非惊厥性癫痫持续状态的流行病学
Epilepsia. 2007;48 Suppl 8:82-4. doi: 10.1111/j.1528-1167.2007.01359.x.
Zotero 插件